PatientsVille.com Logo


Epilim 200mg Medical Research Studies

Up-to-date List of Epilim 200mg Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Epilim 200mg Medical Research Studies

Rank Status Study
1 Recruiting FIRM as a Stand-alone Procedure in the Treatment of Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Procedure: FIRM ablation
Outcome Measures: Single procedure freedom from Atrial Fibrillation (AF) at 12 months.;   Single procedure freedom from Atrial Fibrillation (AF) at 24 months.;   Single procedure freedom from Atrial Fibrillation (AF) at 30 months.
2 Recruiting Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: PVI Ablation;   Procedure: FIRM Ablation
Outcome Measures: Acute Ablation Success for Paroxysmal Atrial Fibrillation;   Long Term Ablation Success for Paroxysmal Atrial Fibrillation
3 Recruiting Manual vs Amigo SmartTouch Atrial Fibrillation Study
Condition: Atrial Fibrillation
Interventions: Procedure: Catheter ablation for Atrial Fibrillation, manual;   Device: Ablation using Amigo remote catheter system
Outcome Measures: Contact force delivered;   Quantity and contiguity of ablation lesions;   Recurrence of atrial fibrillation
4 Recruiting Know Your Pulse Post Stroke-Measurement of Peripheral Pulse for Detection of Atrial Fibrillation After Ischemic Stroke
Conditions: Stroke;   Atrial Fibrillation
Interventions: Behavioral: Measurement of peripheral pulse;   Device: 72h holter ECG
Outcome Measures: Number of newly detected cases of Atrial Fibrillation;   Comparison of detection rates by MPP and by serial holter ECG (3 months, 6 months);   Timepoint of detection of Atrial Fibrillation by MPP or holter ECG;   Modification of secondary preventive medication by detection of Atrial Fibrillation;   Recurrent stroke and mortality
5 Recruiting Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Procedure: Atrial fibrillation ablation
Outcome Measures: Clinical success;   Complete freedom from AF;   Rhythm assessed by % of subjects in sinus rhythm, paroxysmal AF and persistent AF;   Atrial Fibrillation burden;   Role of Pulmonary vein isolation for elimination of Atrial Fibrillation;   Quality of life;   Symptoms Severity Questionnaire and EHRA Symptom Classification;   Biomarkers;   Scar tissue;   Prediction of freedom from AF;   Health economics;   Catheter related complications;   Left and right atrial size and function
6 Unknown  Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management
Condition: Ablation of Atrial Fibrillation
Interventions: Procedure: Pulmonary vein isolation ablation procedure for Atrial Fibrillation;   Procedure: Hybrid procedure for ablation of Atrial Fibrillation;   Procedure: The Cox Maze Procedure for Ablation of Atrial Fibrillation;   Procedure: Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm
Outcome Measures: Return to sinus rhythm rate;   Post procedure morbidities
7 Recruiting Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Condition: Atrial Fibrillation
Intervention: Other: Patients with Atrial Fibrillation
Outcome Measures: Number of major bleeding events;   Number of major adverse cardiac events
8 Recruiting Atrial Fibrillation Progression Trial
Condition: Atrial Fibrillation
Interventions: Device: Left Atrial Ablation (Carto® 3, Carto® XP System, or Carto® RMT and ThermoCool®);   Drug: Rate or Rhythm Control Therapy
Outcome Measures: Time to persistent Atrial Fibrillation/atrial tachycardia excluding isthmus-dependent atrial flutter;   Rate and time to persistent AF/AT;   Rate of persistent AF/AT by number of ablations;   Number of repeat ablations and new antiarrhythmic drugs;   Rhythm (% subjects in Sinus Rhythm, % subjects with recurrent Atrial Fibrillation);   Subject's pre-existing or new onset/worsened condition(s), that may be associated with progression of Atrial Fibrillation;   Catheter-related complications (ablation); adverse drug reactions (AAD);   Health care utilization (number and length of hospitalizations and unscheduled cardiovascular-related visits);   Quality of Life
9 Recruiting Atrial Fibrillation After Cardiac Surgery-comparing Conventional and Miniaturized Bypass Systems
Condition: Atrial Fibrillation
Intervention: Procedure: Miniaturized bypass system
Outcome Measure: Atrial fibrillation
10 Unknown  Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Condition: Heart; Dysfunction Postoperative, Cardiac Surgery
Intervention: Other: Atrial fibrillation
Outcome Measures: Freedom from any episode of post operative Atrial Fibrillation longer than 6 hours duration occurring during the study period.;   Telemetry monitoring strips
11 Recruiting TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation
Condition: Paroxysmal Atrial Fibrillation
Intervention: Device: Catheter ablation for the treatment of paroxysmal Atrial Fibrillation
Outcome Measures: Freedom from recurrence of symptomatic Atrial Fibrillation, atrial tachycardia or atrial flutter;   Incidence of device-related early-onset primary serious adverse events
12 Unknown  Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Procedure: catheter ablation;   Procedure: external electric cardioversion
Outcome Measures: Event-free survival after 6 months (i.e. freedom of atrial tachyarrhythmias - as evaluated in a 7-d-holter, stroke, pulmonary vein stenosis - as evaluated in a CT-/MRT-scan 6 months after the initial procedure - and death).;   success-rate immediately after intervention;   need for re-intervention between 2 and 3 months after initial procedure if not stable sinus rhythm at the two-months follow-up (further ablation/cardioversion);   burden of Atrial Fibrillation in a 7-day-holter after 6 months;   significant improvement in exercise capacity (measured by spiroergometry);   decrease in NT-pro-BNP levels in the blood after 6 months compared to the level before initial intervention;   improvement of quality-of-life (combined questionnaire including the SF-36 form) before initial intervention and at the 6-months follow-up
13 Unknown  CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study
Conditions: Atrial Fibrillation;   Catheter Ablation;   Persistent Atrial Fibrillation;   Pulmonary Vein Isolation
Intervention: Procedure: Atrial fibrillation ablation
Outcome Measures: Recurrence of atrial arrhythmia during 12 months follow up;   Number of periprocedural complications
14 Recruiting The Dynamics of Human Atrial Fibrillation
Conditions: Atrial Fibrillation;   Atrial Tachyarrhythmia
Outcome Measures: Survival Free of Atrial Fibrillation;   Termination of Atrial Fibrillation during ablation
15 Recruiting Atrial Fibrillation Prediction Trial.
Condition: Atrial Fibrillation
Outcome Measures: Atrial Fibrillation Relapse;   Permanent Atrial Fibrillation
16 Recruiting Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation
Condition: Atrial Fibrillation
Interventions: Procedure: Pulmonary vein antrum isolation (PVAI);   Procedure: PVAI plus left atrial posterior wall (LAPW) isolation
Outcome Measures: Outcome of Atrial Fibrillation ablation after permanent pulmonary vein antrum isolation or proven pulmonary vein antrum plus left atrial posterior wall isolation;   Long-term outcome of Atrial Fibrillation ablation after permanent pulmonary vein antrum isolation or proven pulmonary vein antrum plus left atrial posterior wall isolation;   Quality of life after Atrial Fibrillation ablation
17 Not yet recruiting Vitamin C and Atrial Fibrillation After Cardiac Surgery
Condition: Atrial Fibrillation
Interventions: Drug: Ascorbic Acid;   Other: Identical Placebo
Outcome Measures: Post-operative atrial fibrillation;   Hospital length of stay;   Intensive care unit length of stay;   Stroke;   Transient ischemic attack;   Mortality;   Hospital Readmission for atrial fibrillation
18 Recruiting Feasibility Testing of the Alert for Atrial Fibrillation Program
Condition: Atrial Fibrillation
Intervention: Behavioral: Alert for Atrial Fibrillation Program
Outcome Measure: Changes on the Knowledge, Attitudes, and Beliefs about Atrial Fibrillation Survey
19 Recruiting Graz Study on the Risk of Atrial Fibrillation
Conditions: Atrial Fibrillation;   Hypertension;   Diabetes;   Chronic Heart Failure;   Vascular Disease
Intervention: Device: Medtronic Reveal XT implantable loop recorder
Outcome Measures: Time to first diagnosis of atrial fibrillation;   Time to change in therapy based on the diagnosis of Atrial Fibrillation;   Hospitalizations;   Change in NTproBNP serum level associated with occurrence of Atrial Fibrillation;   Death;   Stroke
20 Recruiting Surgical Pulmonary Vein Isolation Efficiency Study
Conditions: Paroxysmal Atrial Fibrillation;   Coronary Artery Disease
Interventions: Procedure: CABG, AVR or CABG+AVR and PVI;   Procedure: CABG, AVR or CABG+AVR
Outcome Measures: Atrial fibrillation burden;   Freedom of symptomatic and asymptomatic Atrial Fibrillation after surgery;   Compare quality of life (QOL) and symptoms, correlation of symptoms with Atrial Fibrillation;   Adverse events after surgery in both arms;   Anti-arrhythmic treatment after surgery;   Hospitalization due to Atrial Fibrillation after surgery;   Cardioversion for the treatment of Atrial Fibrillation after surgery;   Other cardiovascular related events: death, stroke, cardiac infarction, need for revascularization and bleeding

These studies may lead to new treatments and are adding insight into Epilim 200mg etiology and treatment.

A major focus of Epilim 200mg research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Epilim 200mg